Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Gentisic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.95 |
| ▸ | ALOX5 known ✓ | P09917 | 1/20 | 0.95 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.59 |
| ▸ | KDR known ✓ | P35968 | 2/20 | 0.59 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.59 |
| ▸ | EGFR known ✓ | P00533 | 3/20 | 0.58 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.57 |
| ▸ | DHFR known ✓ | P00374 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 4/20 | 0.95 |
| ▸ | CA2 | P00918 | 4/20 | 0.95 |
| ▸ | CA12 | O43570 | 3/20 | 0.95 |
| ▸ | CA7 | P43166 | 3/20 | 0.95 |
| ▸ | CA9 | Q16790 | 3/20 | 0.95 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gentisic Acid SCHEMBL28233271 | 1.00 | CA1 (0.95) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL28945861 | 1.00 | CA1 (0.95) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL8084110 | 0.98 | CA1 (0.91) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL3690 | 0.98 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL29349919 | 0.98 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL2053863 | 0.98 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL30233582 | 0.98 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL8922036 | 0.95 | CA1 (0.95) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL10978035 | 0.95 | CA1 (0.95) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL3981503 | 0.95 | CA1 (0.95) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115636832-A | Pharmaceutically acceptable salts and crystal forms of pyrimido-pyrrole compounds and preparation methods thereof | 江苏先声药业有限公司 | 2023-01-24 | — | — | CN | claimed |
| CN-115636832-A | Pharmaceutically acceptable salts and crystal forms of pyrimido-pyrrole compounds and preparation methods thereof | 江苏先声药业有限公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-114703244-A | Method for reducing trisulfide bonds during recombinant production of polypeptides | 豪夫迈·罗氏有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-114641275-A | Solid compositions comprising a PCSK9 inhibitor and a salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid | 诺和诺德股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114641276-A | Solid compositions comprising a GLP-1 agonist, an SGLT2 inhibitor, and a salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid | 诺和诺德股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-9290492-B2 | Solid forms of antibiotics | LABORATORIOS SENOSIAIN S.A. DE C.V. (MX) | 2016-03-22 | — | — | US | disclosed |
| US-20140088116-A1 | Novel Solid Forms of Antibiotics | LABORATORIOS SENOSIAIN S.A. DE C.V. (MX) | 2014-03-27 | — | — | US | disclosed |
| US-20120065365-A1 | Stable Radiopharmaceutical Compositions and Methods for Their Preparation | BRACCO IMAGING S.P.A. (IT) | 2012-03-15 | — | — | US | disclosed |
| US-20110206606-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREPARATION | BRACCO IMAGING S.P.A. (IT) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206606-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREPARATION | GRPR, GIPR, SSTR3 | PTGS2 4153/4885ALOX5 4125/4885MEN1 143/4885 |
| US-20120065365-A1 | Stable Radiopharmaceutical Compositions and Methods for Their Preparation | GRPR, GIPR, SSTR3 | PTGS2 4078/4885ALOX5 4144/4885MEN1 152/4885 |
| US-20140088116-A1 | Novel Solid Forms of Antibiotics | Q6ZSR9, ABCG2, SFPQ | PTGS2 4586/4885ALOX5 4022/4885MEN1 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.